Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Free Cash Flow (2016 - 2025)

Arcadia Biosciences (RKDA) has disclosed Free Cash Flow for 12 consecutive years, with -$257000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Free Cash Flow rose 85.33% year-over-year to -$257000.0, compared with a TTM value of -$6.1 million through Sep 2025, up 47.66%, and an annual FY2024 reading of -$9.6 million, up 37.15% over the prior year.
  • Free Cash Flow was -$257000.0 for Q3 2025 at Arcadia Biosciences, up from -$2.0 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$257000.0 in Q3 2025 and bottomed at -$9.1 million in Q3 2021.
  • Average Free Cash Flow over 5 years is -$3.7 million, with a median of -$3.4 million recorded in 2022.
  • The sharpest move saw Free Cash Flow crashed 74.01% in 2023, then soared 85.33% in 2025.
  • Year by year, Free Cash Flow stood at -$6.8 million in 2021, then soared by 64.87% to -$2.4 million in 2022, then plummeted by 74.01% to -$4.1 million in 2023, then skyrocketed by 47.36% to -$2.2 million in 2024, then soared by 88.22% to -$257000.0 in 2025.
  • Business Quant data shows Free Cash Flow for RKDA at -$257000.0 in Q3 2025, -$2.0 million in Q2 2025, and -$1.6 million in Q1 2025.